PortfoliosLab logoPortfoliosLab logo
ABCL vs. ABSI
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

ABCL vs. ABSI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AbCellera Biologics Inc. (ABCL) and Absci Corporation (ABSI). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

ABCL vs. ABSI - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ABCL
AbCellera Biologics Inc.
2.05%16.72%-48.69%-43.63%-29.16%-10.79%
ABSI
Absci Corporation
-14.04%33.21%-37.62%100.00%-74.39%-62.02%

Fundamentals

Market Cap

ABCL:

$1.04B

ABSI:

$451.83M

EPS

ABCL:

-$0.49

ABSI:

-$0.82

PS Ratio

ABCL:

13.88

ABSI:

150.70

PB Ratio

ABCL:

1.08

ABSI:

2.38

Total Revenue (TTM)

ABCL:

$75.13M

ABSI:

$2.80M

Gross Profit (TTM)

ABCL:

-$36.22M

ABSI:

-$36.85M

EBITDA (TTM)

ABCL:

-$126.64M

ABSI:

-$112.98M

Returns By Period

In the year-to-date period, ABCL achieves a 2.05% return, which is significantly higher than ABSI's -14.04% return.


ABCL

1D
6.40%
1M
-3.32%
YTD
2.05%
6M
-30.62%
1Y
56.50%
3Y*
-22.65%
5Y*
-35.27%
10Y*

ABSI

1D
8.70%
1M
9.49%
YTD
-14.04%
6M
-1.32%
1Y
19.52%
3Y*
19.68%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ABCL vs. ABSI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABCL
ABCL Risk / Return Rank: 6565
Overall Rank
ABCL Sharpe Ratio Rank: 6767
Sharpe Ratio Rank
ABCL Sortino Ratio Rank: 7070
Sortino Ratio Rank
ABCL Omega Ratio Rank: 6565
Omega Ratio Rank
ABCL Calmar Ratio Rank: 6262
Calmar Ratio Rank
ABCL Martin Ratio Rank: 5959
Martin Ratio Rank

ABSI
ABSI Risk / Return Rank: 5151
Overall Rank
ABSI Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
ABSI Sortino Ratio Rank: 5757
Sortino Ratio Rank
ABSI Omega Ratio Rank: 5353
Omega Ratio Rank
ABSI Calmar Ratio Rank: 4848
Calmar Ratio Rank
ABSI Martin Ratio Rank: 4747
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABCL vs. ABSI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AbCellera Biologics Inc. (ABCL) and Absci Corporation (ABSI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ABCLABSIDifference

Sharpe ratio

Return per unit of total volatility

0.73

0.22

+0.51

Sortino ratio

Return per unit of downside risk

1.61

1.01

+0.60

Omega ratio

Gain probability vs. loss probability

1.18

1.12

+0.06

Calmar ratio

Return relative to maximum drawdown

0.93

0.21

+0.72

Martin ratio

Return relative to average drawdown

1.83

0.39

+1.44

ABCL vs. ABSI - Sharpe Ratio Comparison

The current ABCL Sharpe Ratio is 0.73, which is higher than the ABSI Sharpe Ratio of 0.22. The chart below compares the historical Sharpe Ratios of ABCL and ABSI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


ABCLABSIDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.73

0.22

+0.51

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.53

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.60

-0.36

-0.24

Correlation

The correlation between ABCL and ABSI is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


Dividends

ABCL vs. ABSI - Dividend Comparison

Neither ABCL nor ABSI has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ABCL vs. ABSI - Drawdown Comparison

The maximum ABCL drawdown since its inception was -96.72%, roughly equal to the maximum ABSI drawdown of -96.20%. Use the drawdown chart below to compare losses from any high point for ABCL and ABSI.


Loading graphics...

Drawdown Indicators


ABCLABSIDifference

Max Drawdown

Largest peak-to-trough decline

-96.72%

-96.20%

-0.52%

Max Drawdown (1Y)

Largest decline over 1 year

-54.94%

-54.00%

-0.94%

Max Drawdown (5Y)

Largest decline over 5 years

-94.35%

Current Drawdown

Current decline from peak

-94.07%

-90.10%

-3.97%

Average Drawdown

Average peak-to-trough decline

-83.30%

-84.81%

+1.51%

Ulcer Index

Depth and duration of drawdowns from previous peaks

27.87%

28.35%

-0.48%

Volatility

ABCL vs. ABSI - Volatility Comparison

The current volatility for AbCellera Biologics Inc. (ABCL) is 12.03%, while Absci Corporation (ABSI) has a volatility of 29.96%. This indicates that ABCL experiences smaller price fluctuations and is considered to be less risky than ABSI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


ABCLABSIDifference

Volatility (1M)

Calculated over the trailing 1-month period

12.03%

29.96%

-17.93%

Volatility (6M)

Calculated over the trailing 6-month period

53.26%

70.05%

-16.79%

Volatility (1Y)

Calculated over the trailing 1-year period

78.17%

89.36%

-11.19%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

66.57%

96.13%

-29.56%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

69.65%

96.13%

-26.48%

Financials

ABCL vs. ABSI - Financials Comparison

This section allows you to compare key financial metrics between AbCellera Biologics Inc. and Absci Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
44.85M
650.00K
(ABCL) Total Revenue
(ABSI) Total Revenue
Values in USD except per share items